Nevertheless, as knowledge regarding epigenetic drugs expands, it is expected that the accumulated clinical experience will lead to the development of strategies to accurately assess the therapeutic potential of targeting G9a/GLP in solid and hematological cancers. Here, EHMT2 is linked to hematopoietic and lymphoid cell neoplasm.